{"metadata": {"organization_names": ["augment bone graft"], "person_names_verified": ["tim daniels"], "organization_names_verified": ["aofas", "xr fusion", "radiographic endpoints"], "vars": {}, "entities_rejected": ["autograft", "xr"], "person_names": [], "agreement_id": "d955892fe5853bd4fb7e600d655efd4b25e3d3e381c48fbd0f57d0d09e52a506", "topics": [], "terms": ["**(**", "**(Fisher Exact Test)**", "**(Serious)**", "**(Surgically Related)**", "**(p-value)**", "**AOFAS Ankle-Hindfoot Scale**", "**Age**", "**All Patients**", "**Augment (260)/Autograft (137)**", "**Augment**", "**Augment\u0099 Bone Graft**", "**Augment\u0099**", "**Autograft**", "**BMI**", "**CT Assessment**", "**CT Fusion - 36 wks**", "**CT Fusion Rate**", "**Clinical Endpoints \u0096 52 wks**", "**Clinical Example, Ankle**", "**Clinical Healing**", "**Clinical Success**", "**Complications**", "**Developed as a fully synthetic replacement for autograft**", "**Diagnosis**", "**Disclosure**", "**Discussion/Conclusions**", "**Efficacy:**", "**Excluded from mITT**", "**Foot Fusion Index**", "**Functional Endpoints \u0096 52 wks**", "**Graft Site Pain (any)**", "**HYPOTHESIS**", "**ITT Population**", "**Infections**", "**Joints=203**", "**Joints=394**", "**Missed 36 wk CT-scan**", "**Multiple areas of**", "**N=137**", "**N=142**", "**N=260**", "**N=272**", "**Non- Inferiority**", "**Non-Inferiority**", "**Nonunion**", "**North American Pivotal Trial Review**", "**Not randomized**", "**Not treated**", "**Osseous-bridging**", "**Outcomes of a Randomized, Controlled, Trial to Evaluate Augment Bone Graft (rhPDGF-BB/\u00df-TCP) as a Replacement for Autograft in Hindfoot and Ankle Fusion**", "**P-value**", "**PRIMARY ENDPOINT**", "**Patient Accountability**", "**Pivotal Trial Data Summary**", "**Pivotal Trial Objectives**", "**Post-op**", "**Presented By: Tim Daniels, MD \u0096 Toronto, ON**", "**Prior Studies in Orthopedics**", "**QOL:**", "**Radiographic Assessment**", "**Radiographic Endpoints - 36/52 wks**", "**Radiographic Endpoints -36/52 wks**", "**Radiographic Endpoints \u0096 24 wks**", "**Radiographs and clinical evaluation useful but not always reliable**", "**Randomized Population**", "**Recombinant PDGF (rhPDGF-BB)**", "**Risk Factors**", "**SF-12**", "**Safety Endpoints \u0096 52 wks**", "**Safety Population**", "**Safety:**", "**Screened Population**", "**Serious Treatment Emergent AE\u2019s**", "**Sex**", "**Study Demographics**", "**Study Protocol**", "**Study Scope**", "**Successful fusion but**", "**Therapeutic Failure**", "**VAS Pain Scores**", "**XR Fusion (2 views) - 52 wks**", "**XR Fusion (2 views)**", "**XR Fusion (3 views) - 52 wks**", "**XR Fusion (3 views)**", "**[[Percentage 57]]%**", "**[[Percentage 58]]%**", "**mITT Population**", "**n=149**", "**n=397**", "**prior to treatment**", "**rhPDGF-BB/\u00df-TCP)**"]}}